Breaking News Instant updates and real-time market news.

VRX

Valeant

$13.38

-0.09 (-0.67%)

, MYL

Mylan

$38.15

-0.5 (-1.29%)

10:22
05/19/17
05/19
10:22
05/19/17
10:22

Valeant falls to lows of day after Mylan wins IPR challenge of Apriso patent

Valeant (VRX) shares are down 24c, or 1.8%, to $13.23 after the USPTO posted the text of its decision in the inter partes review of patent no. 8,865,688 related to the drug.

VRX

Valeant

$13.38

-0.09 (-0.67%)

MYL

Mylan

$38.15

-0.5 (-1.29%)

  • 19

    May

  • 22

    May

  • 06

    Jun

  • 24

    Aug

  • 03

    Sep

  • 09

    Oct

VRX Valeant
$13.38

-0.09 (-0.67%)

05/19/17
DBAB
05/19/17
NO CHANGE
Target $18
DBAB
Hold
Deutsche Bank 'warming up' to Valeant story
In a research note titled "Warming up to VRX," Deutsche Bank analyst Gregg Gilbert says that while Valeant Pharmaceuticals is "not out of the woods," the worst fears may be subsiding. The analyst continues to view the company's near-term setup as "encouraging." Valeant's 2017 outlook seems reachable, asset sales in the near- and medium-term seem likely, and the recent refinancing provided more time and flexibility for the company to deal with its issues, Gilbert tells investors. He also believes the worst case for Xifaxan of near-term generic competition "seems to be off the table for now." The analyst keeps a Hold rating on Valeant with an $18 price target. The drugmaker closed yesterday up 22c to $13.47.
05/11/17
WELS
05/11/17
NO CHANGE
Target $9
WELS
Underperform
Valeant estimates reduced on weakening fundamentals at Wells Fargo
Wells Fargo analyst David Maris said the reaction to Valeant's guidance is too positive and notes leverage has increased, most businesses missed his forecasts, and the increase in EBITDA guidance was due to changes in how it accounts for foreign exchange. The analyst lowered estimates and reiterated his Underperform rating given the company's deteriorating fundamentals, adding that he expects the recent share strength to be temporary. However, he increased his price target on the shares to $9 from $8, noting Valeant's Q1 showed a "dramatic decline" in working capital.
05/09/17
JPMS
05/09/17
NO CHANGE
JPMS
Neutral
Valeant's road to recovery remains long, says JPMorgan
JPMorgan analyst Chris Schott finds today's rally in Valeant Pharmaceuticals unsurprising as EBITDA guidance was raised following significant cuts over the past year. That said, the analyst continues to see a "long road to recovery for the story." He keeps a Neutral rating on the shares. Valeant is up 18%, or $1.79, to $11.50 in midday trading.
05/09/17
WELS
05/09/17
NO CHANGE
WELS
Underperform
Valeant key products continue to underperform, says Wells Fargo
Following the company's Q1 results, Wells Fargo analyst David Maris says Valeant Pharmaceuticals' key products continue to underperform. Valeant's decision to highlight in its press release the EBITDA raise of 1.3% is understandable, as this is better than the recent trend, but the $50M raise is relative to approximately $28.9B of total debt, Maris tells investors in a research note. Key products and areas such as Xifaxan and Bausch + Lomb continue to underperform, the analyst contends. He keeps an Underperform rating on Valeant with an $8 price target. The stock in morning trading is up 15%, or $1.48, to $11.19.
MYL Mylan
$38.15

-0.5 (-1.29%)

05/10/17
WELS
05/10/17
NO CHANGE
Target $40
WELS
Market Perform
Mylan deals masking 'weak' organic sales, says Wells Fargo
Wells Fargo analyst David Maris believes Mylan's deals are masking the company's contracting organic growth. When excluding deals, Mylan's total third party sales declined approximately 4% in Q1, with North American Sales down 11%, Europe down 1% and Rest of World up 11%, Maris tells investors in a post-earnings research note. He believes Mylan this morning reported an essentially in-line quarter on earnings, but that organic sales were "weak," particularly in North America. Maris has a Market Perform rating on Mylan with a $40 price target.
05/01/17
BMOC
05/01/17
INITIATION
Target $50
BMOC
Outperform
Mylan initiated with an Outperform at BMO Capital
BMO Capital analyst GaryNachman started Mylan with an Outperform rating and $50 price target. The company is one of the best positioned to navigate through the challenging generic trends over the longer term, the analyst argues.
04/25/17
WELS
04/25/17
NO CHANGE
WELS
Novartis results highlight tough pricing environment, says Wells Fargo
This morning's Q1 results from Novartis' (NVS) Sandoz division highlight the difficult U.S. generic price environment, Wells Fargo analyst David Maris tells investors in a research note. Sandoz experienced pricing erosion of 8% in the quarter, which represents the largest negative impact from pricing in recent quarters, Maris writes. He expects the negative U.S. pricing environment to impact including Mallinckrodt (MNK), Teva (TEVA), Mylan (MYL) and Perrigo (PRGO). Maris remains cautious on the pricing environment for generics.
04/11/17
WELS
04/11/17
NO CHANGE
WELS
Market Perform
Wells unsure of risk to Mylan from FDA warning letter
Wells Fargo analyst David Maris says he does not know what products, if any, are manufactured at Mylan's India-based plant that received the warning letter from the FDA. As such, the letter may have little or no immediate commercial risk, Maris tells investors in an intraday research note. The analyst questions whether the FDA will stop letting drugs from this facility into the U.S. He adds that to him, "nothing is more critical for a brand or generic drug company than being able to ensure that its products are safe and effective." Maris keeps a Market Perform rating on Mylan.

TODAY'S FREE FLY STORIES

TTNP

Titan Pharmaceuticals

$1.90

-0.1 (-5.00%)

17:49
10/19/17
10/19
17:49
10/19/17
17:49
Hot Stocks
Titan Pharmaceuticals presents non-clinical data from liothyronine implant »

Titan Pharmaceuticals is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MSA

MSA Safety

$82.20

1.37 (1.69%)

17:46
10/19/17
10/19
17:46
10/19/17
17:46
Earnings
MSA Safety reports Q3 EPS 92c, consensus 80c »

Reports Q3 revenue $296M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Oct

SKX

Skechers

$24.03

-1.06 (-4.22%)

, CAI

CAI International

$31.38

-0.05 (-0.16%)

17:41
10/19/17
10/19
17:41
10/19/17
17:41
Hot Stocks
On The Fly: After Hours Movers »

UP AFTER EARNINGS:…

SKX

Skechers

$24.03

-1.06 (-4.22%)

CAI

CAI International

$31.38

-0.05 (-0.16%)

PYPL

PayPal

$67.25

-0.01 (-0.01%)

MXIM

Maxim Integrated

$50.09

0.24 (0.48%)

IMDZ

Immune Design

$5.50

-1.05 (-16.03%)

NCR

NCR Corp.

$37.05

-0.26 (-0.70%)

TACO

Del Taco

$15.39

-0.01 (-0.06%)

ATHN

athenahealth

$116.41

-4.37 (-3.62%)

ISRG

Intuitive Surgical

$357.46

3.09 (0.87%)

ETFC

E-Trade

$43.69

-0.23 (-0.52%)

CELG

Celgene

$135.96

-1.21 (-0.88%)

PBMD

Prima BioMed

$2.36

-0.02 (-0.84%)

AAXN

Axon

$24.62

-0.37 (-1.48%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

  • 19

    Oct

  • 19

    Oct

  • 19

    Oct

  • 19

    Oct

  • 19

    Oct

  • 19

    Oct

  • 19

    Oct

  • 19

    Oct

  • 20

    Oct

  • 21

    Oct

  • 22

    Oct

  • 26

    Oct

  • 28

    Oct

  • 06

    Nov

  • 06

    Nov

  • 07

    Nov

  • 08

    Nov

  • 29

    Nov

DGX

Quest Diagnostics

$93.23

1.18 (1.28%)

17:37
10/19/17
10/19
17:37
10/19/17
17:37
Hot Stocks
Quest Diagnostics acquires Cleveland HeartLab, terms not disclosed »

Advantage Capital…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

  • 06

    Nov

  • 30

    Nov

AAXN

Axon

$24.62

-0.37 (-1.48%)

17:34
10/19/17
10/19
17:34
10/19/17
17:34
Hot Stocks
Axon says now aware of comment letter over SEC's review of 10-K, 10-Q »

Axon Enterprise said in a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BPMX

BioPharmX

17:29
10/19/17
10/19
17:29
10/19/17
17:29
Syndicate
Breaking Syndicate news story on BioPharmX »

BioPharmX files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MBVX

MabVax Therapeutics

$0.74

0.0248 (3.47%)

17:29
10/19/17
10/19
17:29
10/19/17
17:29
Syndicate
Breaking Syndicate news story on MabVax Therapeutics »

MabVax Therapeutics files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IBKC

Iberiabank

$80.15

0.05 (0.06%)

17:28
10/19/17
10/19
17:28
10/19/17
17:28
Earnings
Iberiabank reports Q3 non-GAAP EPS $1.00, consensus $1.16 »

Reports Q3 core revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Oct

  • 15

    Nov

  • 28

    Nov

DRRX

Durect

$1.97

0.03 (1.55%)

17:28
10/19/17
10/19
17:28
10/19/17
17:28
Hot Stocks
Breaking Hot Stocks news story on Durect »

Durect trading halted,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

QCP

Quality Care Properties

$16.26

0.07 (0.43%)

17:26
10/19/17
10/19
17:26
10/19/17
17:26
Hot Stocks
Quality Care Properties provides update on HCR ManorCare »

Quality Care Properties…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FTR

Frontier Communications

$11.48

0.02 (0.17%)

, CHH

Choice Hotels

$68.45

0.25 (0.37%)

17:26
10/19/17
10/19
17:26
10/19/17
17:26
Hot Stocks
Frontier Communications named a Qualified Vendor with Choice Hotels Internationa »

Frontier Communications…

FTR

Frontier Communications

$11.48

0.02 (0.17%)

CHH

Choice Hotels

$68.45

0.25 (0.37%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Oct

  • 06

    Nov

  • 08

    Nov

DRIO

DarioHealth

$1.98

-0.2 (-9.17%)

17:16
10/19/17
10/19
17:16
10/19/17
17:16
Syndicate
Breaking Syndicate news story on DarioHealth  »

DarioHealth files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CUBI

Customers Bancorp

$33.16

0.46 (1.41%)

17:11
10/19/17
10/19
17:11
10/19/17
17:11
Hot Stocks
Customers Bancorp to spin off BankMobile business »

Customers Bancorp plans…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

  • 15

    Nov

MVC

MVC Capital

$10.40

0.08 (0.78%)

17:07
10/19/17
10/19
17:07
10/19/17
17:07
Hot Stocks
MVC Capital: Glass Lewis, Egan-Jones against proposal to cease new investments »

MVC Capital announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Oct

CELG

Celgene

$135.96

-1.21 (-0.88%)

17:05
10/19/17
10/19
17:05
10/19/17
17:05
Hot Stocks
Breaking Hot Stocks news story on Celgene »

Celgene down 6.6% after…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Oct

  • 28

    Oct

  • 06

    Nov

  • 08

    Nov

NGD

New Gold

$3.57

0.03 (0.85%)

17:03
10/19/17
10/19
17:03
10/19/17
17:03
Hot Stocks
New Gold says Rainy River Mine achieves commercial production »

New Gold reported that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Oct

COR

CoreSite Realty

$114.84

0.01 (0.01%)

17:02
10/19/17
10/19
17:02
10/19/17
17:02
Syndicate
Breaking Syndicate news story on CoreSite Realty »

CoreSite Realty files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Oct

  • 13

    Nov

SXT

Sensient

$78.26

-0.43 (-0.55%)

17:02
10/19/17
10/19
17:02
10/19/17
17:02
Earnings
Breaking Earnings news story on Sensient »

Sensient backs FY17…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Oct

WHG

Westwood Holdings Group

$69.16

0.58 (0.85%)

17:01
10/19/17
10/19
17:01
10/19/17
17:01
Hot Stocks
Westwood Holdings Group settles lawsuit »

AGF, Westwood, Patricia…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Oct

SXT

Sensient

$78.26

-0.43 (-0.55%)

17:01
10/19/17
10/19
17:01
10/19/17
17:01
Earnings
Sensient reports Q3 adjusted EPS 89c, consensus 88c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Oct

GPP

Green Plains Partners

$19.50

-0.05 (-0.26%)

17:00
10/19/17
10/19
17:00
10/19/17
17:00
Hot Stocks
Green Plains Partners raises quarterly distribution 1c to 46c per unit »

Green Plains Partners…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CELG

Celgene

$135.96

-1.21 (-0.88%)

17:00
10/19/17
10/19
17:00
10/19/17
17:00
Hot Stocks
Breaking Hot Stocks news story on Celgene 

Celgene trading resumes

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Oct

  • 28

    Oct

  • 06

    Nov

  • 08

    Nov

NSM

Nationstar

$19.71

-0.43 (-2.14%)

16:59
10/19/17
10/19
16:59
10/19/17
16:59
Periodicals
Nationstar working with advisors on strategic options, Betaville says 

Reference Link

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CLW

Clearwater Paper

16:59
10/19/17
10/19
16:59
10/19/17
16:59
Earnings
Clearwater Paper sees Q4 adjusted EPS 71c-$1.04, consensus 94c »

Sees Q4 net sales up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

ISRG

Intuitive Surgical

$357.46

3.09 (0.87%)

16:58
10/19/17
10/19
16:58
10/19/17
16:58
Hot Stocks
Intuitive Surgical raises FY17 procedure growth view 15%-16% from 14%-15% »

Sees FY17 pro forma gross…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.